Strut cuts tirzepatide to $149 a month
Also in this issue: Wellorithm raises both drugs $50
Forwarded this? Get it weekday mornings.
Take. Compounded GLP-1 prices are splitting, not falling as a pack. Strut cut its tirzepatide floor while Wellorithm raised both drugs by $50 a month. Patients will compare a clinic to whichever of those two groups they shop. We'd pick one lane on the page and say what the price includes.
Strut Health now lists injectable tirzepatide "Starting at $149/mo" on its auto-refill vial page, down from $219 late last month. The page ties the floor to dose. Higher tiers aren't shown.
The same week, Wellorithm raised compounded semaglutide to $299 a month after a $179 first month, up from $247 and $147. Tirzepatide rose to $399 after a $279 first month, up from $349 and $249. Those ongoing prices are flat across the doses on its pricing table. Consult and delivery show as included on that page.
A three-seller sample isn't a market. Strut's $149 is a lowest-dose floor. Wellorithm hasn't said why it raised. Still, the low end keeps cutting while at least one mid-priced seller moved up. Clinics priced in the middle get squeezed from both sides.
Supply
Irving 503B recalls 4,675 office-use testosterone vials
Right Value Drug Stores LLC, doing business as Carie Boyd's Prescription Shop in Irving, Texas, recalled 4,675 vials of compounded testosterone cypionate 200 mg/mL in 5 mL and 30 mL vials labeled "Office Use Only." FDA's enforcement record lists the recall as Class II, firm-initiated, classified mid-October, and ongoing nationwide. The reason is lack of sterility assurance.
The firm is on FDA's registered outsourcing facilities list (content current as of late October). It first registered in 2019. Its most recent registration and last inspection both fall in September, with a Form 483 and the inspection action still "Open." It told FDA it intends to compound sterile drugs from bulk. FDA sent the firm a warning letter in December 2024 that cited, among other things, testosterone cypionate labels missing inactive-ingredient information. That letter is history. It is not a finding about these lots.
This is a 503B selling office stock to clinics, not a 503A filling patient prescriptions. Those lots can end up in clinic fridges. TRT and HRT clinics that buy office-use testosterone from outside suppliers should check their lots against FDA's record. Lot codes stay on the FDA page.
The Signal
Coverage
Medicare conversion factor falls 2.31% for 2027
CMS finalized the CY2027 Physician Fee Schedule on Wednesday. Per the HHS release and trade write-ups of CMS's fact sheet, the conversion factor for most clinicians drops from $33 to $33, or 2.31%. Qualifying APM participants fall 1.83% to $33. Both cuts are deeper than the July proposal. The rule takes effect in January 2027. When an office visit and a minor procedure land the same day, the lower-cost service is paid at 80%. Medicare telehealth flexibilities stay through the end of 2027 by statute. Claims will need the BB and BC modifiers from that January. A rule that would have limited remote monitoring to practice-employed staff is delayed to 2029.
Clinics that bill Medicare next to cash-pay hormone or weight work get paid less per unit in 2027. Anyone on a telehealth platform contract has a new claims modifier to set up before January.
Marketing
NAD tells Good Life Meds to drop Tirzepatide+ claims
In a Lilly challenge decided Wednesday, BBB National Programs' National Advertising Division recommended that Good Life Meds stop express health-benefit and personalization claims for compounded "Tirzepatide+" and change ads that imply safety, results and weight loss. NAD said the record did not evaluate the safety of combining tirzepatide with the additives. It said FDA allowing compounding during shortages does not substantiate the claims. Good Life said it disagrees with parts of the decision and will comply. This is a self-regulatory recommendation, not an FDA action or a court order. "+" blends with add-ins are what Lilly challenged.
Operator Q&A
Patients ask if their GLP-1 came from a 503A or a 503B
A patient forum thread this week asked which pharmacy type matters. Under the statute, a 503B can compound from bulk only when the substance is on FDA's 503B bulks list or the finished drug is on the shortage list. FDA proposed in May not to put semaglutide, tirzepatide or liraglutide on that list. Its April warning letter to 503B ProRx cited tirzepatide compounded from bulk for exactly that reason. Compounded GLP-1 sold to patients today generally comes from 503A pharmacies filling individual prescriptions. The May item is a proposal, not a final list decision.
Medspa
Bios buys Houston's Dr. Shel Wellness
Practice Transitions Group said Monday it advised the Houston sale to Bios Wellness Clinics. Terms weren't disclosed.
Wire
- FuturHealth's first-day Chapter 11 declaration puts an about $14 million iHeartMedia ad deal that "failed to produce the anticipated return" ahead of pricing as the first cash drain, with more than $4 million paid in the first half of 2025 and about $8 million still owed, per the Stretto filing.
- Hims & Hers reports third-quarter results Monday after the close, with a call at 5:00 PM ET, per its investor site.
- Liraglutide remains on FDA's shortage list. Novo's Saxenda pack (NDC 0169-2800-15) shows as to be discontinued in openFDA shortages data.
- Comments on HHS's 503A peptide enforcement-discretion policy close next Friday (docket HHS-OASH-2026-0496). Enforcement discretion is not approval.
Optimized Daily Report is business news for clinic operators. Not medical, legal, or investment advice. Company claims are the company's.